GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannara Biotech Inc (STU:8CB0) » Definitions » Cash Conversion Cycle

Cannara Biotech (STU:8CB0) Cash Conversion Cycle : 248.40 (As of Feb. 2025)


View and export this data going back to 2019. Start your Free Trial

What is Cannara Biotech Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Cannara Biotech's Days Sales Outstanding for the three months ended in Feb. 2025 was 49.
Cannara Biotech's Days Inventory for the three months ended in Feb. 2025 was 272.38.
Cannara Biotech's Days Payable for the three months ended in Feb. 2025 was 72.98.
Therefore, Cannara Biotech's Cash Conversion Cycle (CCC) for the three months ended in Feb. 2025 was 248.40.


Cannara Biotech Cash Conversion Cycle Historical Data

The historical data trend for Cannara Biotech's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cannara Biotech Cash Conversion Cycle Chart

Cannara Biotech Annual Data
Trend Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
Cash Conversion Cycle
Get a 7-Day Free Trial -743.94 44.64 161.57 281.54 249.03

Cannara Biotech Quarterly Data
May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 183.06 234.68 261.68 229.77 248.40

Competitive Comparison of Cannara Biotech's Cash Conversion Cycle

For the Drug Manufacturers - Specialty & Generic subindustry, Cannara Biotech's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cannara Biotech's Cash Conversion Cycle Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cannara Biotech's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Cannara Biotech's Cash Conversion Cycle falls into.


;
;

Cannara Biotech Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Cannara Biotech's Cash Conversion Cycle for the fiscal year that ended in Aug. 2024 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=53.33+262.24-66.54
=249.03

Cannara Biotech's Cash Conversion Cycle for the quarter that ended in Feb. 2025 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=49+272.38-72.98
=248.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cannara Biotech  (STU:8CB0) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Cannara Biotech Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Cannara Biotech's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Cannara Biotech Business Description

Traded in Other Exchanges
Address
1055 West Georgia Street, Suite 2050, Vancouver, BC, CAN, V6E 3P3
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .

Cannara Biotech Headlines

No Headlines